Study of use of Ayurveda Intervention (Ayush-64) in COVID 19

Evaluation of Efficacy and Safety of Ayurveda Intervention (Ayush-64) add-on therapy for patients with COVID-19 infection (Stage I)-An Open labelled, Parallel Group, Randomized controlled clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/06/026002

Enrollment

Registered

2020-06-21

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: AYUSH 64: 2 Capsules/Tablets (500mg each) thrice daily by oral route for one month Control Intervention1: Standard treatments as per guidelines: NA

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of 18-60 yrs of age, clinically diagnosed with corona virus disease 2019 by RTPCR test coming under stage I- mild (Early infection) 2. Participants who can take medicines orally. 3. Patients willing to provide signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant, Lactating women, patients with CKD (Chronic Kidney Disease). 2. Not willing to participate in the study.

Design outcomes

Primary

Measure	Time frame
Clinical cure rate: Time to negative conversion of COVID19.Timepoint: Time to event	—

Secondary

Measure	Time frame
Duration of fever and each of the respiratory symptomsTimepoint: Baseline to one month;Improvement in hematological and laboratory parameters (CBC, LFT, RFT, RBS, ESR, Hs-CRP, LDH, CXR, ABG, S. Ferritin, D-dimer, ECG)Timepoint: Baseline to one month;No of cases Reporting any ADR/AETimepoint: Baseline to one month;Number of cases that progressed to multi-organ failure while under clinical trialTimepoint: Baseline to one month;Number of cases that required invasive or non-invasive oxygen therapy during the intervention.Timepoint: Baseline to one month;Number of patients referredTimepoint: Baseline to one month	—

Measure

Time frame

Duration of fever and each of the respiratory symptomsTimepoint: Baseline to one month;Improvement in hematological and laboratory parameters (CBC, LFT, RFT, RBS, ESR, Hs-CRP, LDH, CXR, ABG, S. Ferritin, D-dimer, ECG)Timepoint: Baseline to one month;No of cases Reporting any ADR/AETimepoint: Baseline to one month;Number of cases that progressed to multi-organ failure while under clinical trialTimepoint: Baseline to one month;Number of cases that required invasive or non-invasive oxygen therapy during the intervention.Timepoint: Baseline to one month;Number of patients referredTimepoint: Baseline to one month

—

Countries

India

Contacts

Public ContactProf Pawan kumar Godatwar

All India Institute of Medical Sciences, Jodhpur

dr.jaykaran78@gmail.com9825219196

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026